Inspection Readiness as a Steady State: Building the Quality Organization That Is Ready on an Ordinary Tuesday

FDA inspection readiness can no longer be treated as a short-term preparation exercise before an expected inspection. For pharmaceutical, biotechnology, and medical device organizations, maintaining continuous inspection readiness means building a quality system that produces evidence of compliance during everyday operations—not just when an inspection is approaching.

This white paper explores how organizations can strengthen FDA inspection readiness through continuous quality management, effective FDA inspection preparation, evidence-based Form 483 response practices, record retrieval, backlog management, and inspection team training. It also examines the changing regulatory environment, including QMSR requirements for medical device manufacturers, and provides a practical roadmap for building a quality organization that is prepared for an FDA inspection on any ordinary day.

Fill out the form to receive our White Paper.